非酒精性脂肪性肝病在研新药的进展

徐昆; 张旭; 李瑛; 胡振斌

doi:10.3969/j.issn.1001-5256.2021.07.047

非酒精性脂肪性肝病在研新药的进展

DOI: 10.3969/j.issn.1001-5256.2021.07.047

徐昆¹,
张旭¹,
李瑛¹,
胡振斌^2, ,

1.
广西中医药大学研究生院，南宁 530222
2.
广西中医药大学第一附属医院肝病一区，南宁 530023

基金项目:

国家十三五“艾滋病和病毒性肝炎等重大传染病防治”科技重大专项基金 (2018ZX10725505-002)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：胡振斌负责课题设计, 修改论文, 指导撰写文章并最后定稿; 徐昆负责拟定写作思路, 资料分析, 撰写论文; 张旭、李瑛负责收集数据。

详细信息

通信作者:
胡振斌，huzhenbin123@163.com

中图分类号: R575.5
计量
- 文章访问数: 446
- HTML全文浏览量: 120
- PDF下载量: 68
- 被引次数: 0
出版历程
- 收稿日期: 2020-11-23
- 录用日期: 2021-01-11
- 出版日期: 2021-07-20

Advances in investigational new drugs for nonalcoholic fatty liver disease

Kun XU¹,
Xu ZHANG¹,
Ying LI¹,
Zhenbin HU^{2
, ,}

1.
Graduate School of Guangxi University of Chinese Medicine, Nanning 530222, China
2.
First Ward of Hepatology, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning 530023, China

Research funding:

The National Thirteenth Five-Year Plan"Prevention and Treatment of Major Infectious Diseases such as AIDS and Viral Hepatitis" Science and Technology Major Special Fund Project (2018ZX10725505-002)

摘要

摘要: 非酒精性脂肪性肝病(NAFLD)是全世界最常见的肝脏疾病，与肥胖、胰岛素抵抗和其他代谢性疾病密切相关。目前尚无批准用于治疗的药物，常规的生活方式管理也难以对疾病产生积极的影响。对目前在研的代谢调节剂、抗炎抗氧化剂及抗纤维化剂等NAFLD治疗药物进行了综述，归纳总结了其临床研究结果，为NAFLD的临床治疗及药物研发提供新思路。
- 非酒精性脂肪性肝病 /
- 药物, 临床试用 /
- 抗氧化剂
Abstract: Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide and is closely associated with obesity, insulin resistance, and other metabolic diseases. There are currently no drugs approved for treatment, and routine lifestyle management can hardly have a positive impact on this disease. This article reviews the investigational new drugs for NAFLD, including metabolic regulators, anti-inflammatory antioxidants, and anti-fibrosis agents, and summarizes the results of their clinical studies, so as to provide new ideas for the clinical treatment of NAFLD and the and development of related drugs.
- Nonalcoholic Fatty Liver Disease /
- Drugs, Investigational /
- Antioxidants

HTML全文

参考文献(43)

[1]	SVEN MF, PIERRE B, MANAL FA, et al. A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: Design of the NATIVE study[J]. Contemp Clin Trials, 2020, 98: 106170. DOI: 10.1016/j.cct.2020.106170.
[2]	KABBANY MN, CONJEEVARAM SELVAKUMAR PK, WATT K, et al. Prevalence of nonalcoholic steatohepatitis-associated cirrhosis in the United States: An analysis of national health and nutrition examination survey data[J]. Am J Gastroenterol, 2017, 112(4): 581-587. DOI: 10.1038/ajg.2017.5.
[3]	POLYZOS SA, KOUNTOURAS J, MANTZOROS CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics[J]. Metabolism, 2019, 92: 82-97. DOI: 10.1016/j.metabol.2018.11.014.
[4]	FRANCQUE S, SZABO G, ABDELMALEK MF, et al. Nonalcoholic steatohepatitis: The role of peroxisome proliferator-activated receptors[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(1): 24-39. DOI: 10.1038/s41575-020-00366-5.
[5]	BOUGARNE N, WEYERS B, DESMET SJ, et al. Molecular actions of PPARα in lipid metabolism and inflammation[J]. Endocr Rev, 2018, 39(5): 760-802. DOI: 10.1210/er.2018-00064.
[6]	STAELS B, RUBENSTRUNK A, NOEL B, et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis[J]. Hepatology, 2013, 58(6): 1941-1952. DOI: 10.1002/hep.26461.
[7]	RATZIU V, HARRISON SA, FRANCQUE S, et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening[J]. Gastroenterology, 2016, 150(5): 1147-1159.e5. DOI: 10.1053/j.gastro.2016.01.038.
[8]	WESTEROUEN VAN MEETEREN MJ, DRENTH J, TJWA E. Elafibranor: A potential drug for the treatment of nonalcoholic steatohepatitis (NASH)[J]. Expert Opin Investig Drugs, 2020, 29(2): 117-123. DOI: 10.1080/13543784.2020.1668375.
[9]	TANG JT, MAO YM. Development of new drugs for the treatment of nonalcoholic steatohepatitis[J]. J Dig Dis, 2020, 21(1): 3-11. DOI: 10.1111/1751-2980.12830.
[10]	COLCA JR, McDONALD WG, ADAMS WJ. MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis[J]. Expert Opin Investig Drugs, 2018, 27(7): 631-636. DOI: 10.1080/13543784.2018.1494153.
[11]	HARRISON SA, ALKHOURI N, DAVISON BA, et al. Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase Ⅱb study[J]. J Hepatol, 2020, 72(4): 613-626. DOI: 10.1016/j.jhep.2019.10.023.
[12]	JONES D, BOUDES PF, SWAIN MG, et al. Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: A double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study[J]. Lancet Gastroenterol Hepatol, 2017, 2(10): 716-726. DOI: 10.1016/S2468-1253(17)30246-7.
[13]	GOTTLIEB A, CANBAY A. Why bile acids are so important in non-alcoholic fatty liver disease (NAFLD) progression[J]. Cells, 2019, 8(11). DOI: 10.3390/cells8111358.
[14]	PELLICCIARI R, COSTANTINO G, CAMAIONI E, et al. Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid[J]. J Med Chem, 2004, 47(18): 4559-4569. DOI: 10.1021/jm049904b.
[15]	NEUSCHWANDER-TETRI BA, LOOMBA R, SANYAL AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial[J]. Lancet, 2015, 385(9972): 956-965. DOI: 10.1016/S0140-6736(14)61933-4.
[16]	ZOBAIR Y, VLAD R, ROHIT L, et al. GS-06-positive results from REGENERATE: A phase 3 international, randomized, placebo-controlled study evaluating obeticholic acid treatment for NASH[J]. J Hepatol, 2019, 70(1): e5. DOI: 10.1016/SO618-8278(19)30006-4.
[17]	PATEL K, HARRISON SA, ELKHASHAB M, et al. Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: A phase 2 randomized controlled trial[J]. Hepatology, 2020, 72(1): 58-71. DOI: 10.1002/hep.31205.
[18]	HARRISON SA, BASHIR MR, LEE KJ, et al. A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis[J]. J Hepatol, 2021, 75(1): 25-33. DOI: 10.1016/j.jhep.2021.01.047.
[19]	KEVIN K, WANG YJ, RANDALL H, et al. FRI-313-A novel farnesoid X receptor agonist, TERN-101, reduces liver steatosis, inflammation, ballooning and fibrosis in a murine model of non-alcoholic steatohepatitis[J]. J Hepatol, 2019, 70(1): e534.
[20]	FIORUCCI S, BIAGIOLI M, SEPE V, et al. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH)[J]. Expert Opin Investig Drugs, 2020, 29(6): 623-632. DOI: 10.1080/13543784.2020.1763302.
[21]	BERNSMEIER C, MEYER-GERSPACH AC, BLASER LS, et al. Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease[J]. PLoS One, 2014, 9(1): e87488. DOI: 10.1371/journal.pone.0087488.
[22]	ARMSTRONG MJ, GAUNT P, AITHAL GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study[J]. Lancet, 2016, 387(10019): 679-690. DOI: 10.1016/S0140-6736(15)00803-X.
[23]	NAUCK M, FRID A, HERMANSEN K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (liraglutide effect and action in diabetes)-2 study[J]. Diabetes Care, 2009, 32(1): 84-90. DOI: 10.2337/dc08-1355.
[24]	KATSIKI N, ATHYROS VG, KARAGIANNIS A, et al. Semaglutide, lipid-lowering drugs, and NAFLD[J]. Lancet Diabetes Endocrinol, 2017, 5(5): 329-330. DOI: 10.1016/S2213-8587(17)30109-2.
[25]	AMBERY P, PARKER VE, STUMVOLL M, et al. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: A randomised, controlled, double-blind, ascending dose and phase 2a study[J]. Lancet, 2018, 391(10140): 2607-2618. DOI: 10.1016/S0140-6736(18)30726-8.
[26]	FRIAS JP, NAUCK MA, VAN J, et al. Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens[J]. Diabetes Obes Metab, 2020, 22(6): 938-946. DOI: 10.1111/dom.13979.
[27]	TONG L. Acetyl-coenzyme A carboxylase: Crucial metabolic enzyme and attractive target for drug discovery[J]. Cell Mol Life Sci, 2005, 62(16): 1784-1803. DOI: 10.1007/s00018-005-5121-4.
[28]	HARRIMAN G, GREENWOOD J, BHAT S, et al. Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats[J]. Proc Natl Acad Sci U S A, 2016, 113(13): e1796-e1805. DOI: 10.1073/pnas.1520686113.
[29]	STIEDE K, MIAO W, BLANCHETTE HS, et al. Acetyl-coenzyme A carboxylase inhibition reduces de novo lipogenesis in overweight male subjects: A randomized, double-blind, crossover study[J]. Hepatology, 2017, 66(2): 324-334. DOI: 10.1002/hep.29246.
[30]	LOOMBA R, KAYALI Z, NOUREDDIN M, et al. GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease[J]. Gastroenterology, 2018, 155(5): 1463-1473.e6. DOI: 10.1053/j.gastro.2018.07.027.
[31]	DEGIROLAMO C, SABBÀ C, MOSCHETTA A. Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23[J]. Nat Rev Drug Discov, 2016, 15(1): 51-69. DOI: 10.1038/nrd.2015.9.
[32]	HARRISON SA, RINELLA ME, ABDELMALEK MF, et al. NGM282 for treatment of non-alcoholic steatohepatitis: A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet, 2018, 391(10126): 1174-1185. DOI: 10.1016/S0140-6736(18)30474-4.
[33]	ZHANG F, YU L, LIN X, et al. Minireview: Roles of fibroblast growth factors 19 and 21 in metabolic regulation and chronic diseases[J]. Mol Endocrinol, 2015, 29(10): 1400-1413. DOI: 10.1210/me.2015-1155.
[34]	NOUREDDIN M, VIPANI A, BRESEE C, et al. NASH leading cause of liver transplant in women: Updated analysis of indications for liver transplant and ethnic and gender variances[J]. Am J Gastroenterol, 2018, 113(11): 1649-1659. DOI: 10.1038/s41395-018-0088-6.
[35]	KRAUSE C, GROHS M, EL GAMMAL AT, et al. Reduced expression of thyroid hormone receptor β in human nonalcoholic steatohepatitis[J]. Endocr Connect, 2018, 7(12): 1448-1456. DOI: 10.1530/EC-18-0499.
[36]	HARRISON SA, BASHIR MR, GUY CD, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet, 2019, 394(10213): 2012-2024. DOI: 10.1016/S0140-6736(19)32517-6.
[37]	FERNÁNDEZ-RAMOS D, LOPITZ-OTSOA F, DELACRUZ-VILLAR L, et al. Arachidyl amido cholanoic acid improves liver glucose and lipid homeostasis in nonalcoholic steatohepatitis via AMPK and mTOR regulation[J]. World J Gastroenterol, 2020, 26(34): 5101-5117. DOI: 10.3748/wjg.v26.i34.5101.
[38]	SUMIDA Y, YONEDA M, OGAWA Y, et al. Current and new pharmacotherapy options for non-alcoholic steatohepatitis[J]. Expert Opin Pharmacother, 2020, 21(8): 953-967. DOI: 10.1080/14656566.2020.1744564.
[39]	LEE YA, WALLACE MC, FRIEDMAN SL. Pathobiology of liver fibrosis: A translational success story[J]. Gut, 2015, 64(5): 830-841. DOI: 10.1136/gutjnl-2014-306842.
[40]	LEFERE S, DEVISSCHER L, TACKE F. Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: Opportunities and challenges[J]. Expert Opin Investig Drugs, 2020, 29(2): 89-92. DOI: 10.1080/13543784.2020.1718106.
[41]	FRIEDMAN SL, RATZIU V, HARRISON SA, et al. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis[J]. Hepatology, 2018, 67(5): 1754-1767. DOI: 10.1002/hep.29477.
[42]	YOON YC, FANG Z, LEE JE, et al. Selonsertib inhibits liver fibrosis via downregulation of ASK1/MAPK pathway of hepatic stellate cells[J]. Biomol Ther (Seoul), 2020, 28(6): 527-536. DOI: 10.4062/biomolther.2020.016.
[43]	CHALASANI N, ABDELMALEK MF, GARCIA-TSAO G, et al. Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension[J]. Gastroenterology, 2020, 158(5): 1334-1345.e5. DOI: 10.1053/j.gastro.2019.11.296.